US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aardvark Therapeutics

13.39

-0.4700-3.39%

Post-market: 12.91-0.4800-3.58%17:55 EDT

Volume:676.86K

Turnover:9.06M

Market Cap:286.34M

PE:-20.66

High:14.00

Open:14.00

Low:12.86

Close:13.86

Loading ...

Overview Company News Filings

Aardvark Therapeutics Announces Phase 3 HERO Study Enrollment for ARD-101 in Prader-Willi Syndrome at 2025 United in Hope Conference

Aardvark Therapeutics appoints Timothy Kieffer as CSO, Danny Villeneuve as CCO

Aardvark Therapeutics Inc. Strengthens Leadership Team with Key Appointments in Scientific, Commercial, Regulatory, and Legal Roles

Press Release: Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

Aardvark Therapeutics Is Maintained at Outperform by RBC Capital

Aardvark Therapeutics Inc trading resumes

Aardvark Therapeutics Inc trading halted, volatility trading pause

RBC Trims Price Target on Aardvark Therapeutics to $20 From $21, Keeps Outperform, Speculative Risk

MT Newswires Live

BRIEF-Aardvark Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

Aardvark Therapeutics Q1 EPS $(0.71) Down From $(0.55) YoY

Aardvark Therapeutics Reports Q1 2025 Results: Net Loss Widens to $9.3M; R&D Expenses Surge

Aardvark Therapeutics Inc - as of March 31, 2025, Aardvark Had Cash, Cash Equivalents, and Short-Term Investments of $151.3 Mln

THOMSON REUTERS

Aardvark Therapeutics Price Target Maintained With a $50.00/Share by Cantor Fitzgerald

Aardvark Therapeutics FY24 EPS (5.15) Down From ($1.82) YoY

Press Release: Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

BUZZ-Ultragenyx Pharma up after JPMorgan PT raise

Aardvark Therapeutics Is Maintained at Buy by B of A Securities

Aardvark Therapeutics price target raised to $26 from $22 at BofA

Aardvark Therapeutics Inc : Bofa Global Research Initiates Coverage With Buy Rating; Price Objective $22

THOMSON REUTERS

BofA Initiates Aardvark Therapeutics at Buy With $22 Price Target

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/AARD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AARD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":13.39,"timestamp":1751054400000,"preClose":13.86,"halted":0,"volume":676862,"hourTrading":{"tag":"盘后","latestPrice":12.91,"preClose":13.39,"latestTime":"17:55 EDT","volume":73421,"amount":983049.47,"timestamp":1751061317820},"delay":0,"floatShares":5900000,"shares":21384400,"eps":-0.648,"marketStatus":"Closed","change":-0.47,"latestTime":"06-27 16:00:00 EDT","open":14,"high":14,"low":12.855,"amount":9058616.068948,"amplitude":0.082612,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.648,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":5,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":13.86,"postHourTrading":{"tag":"盘后","latestPrice":12.91,"preClose":13.39,"latestTime":"17:55 EDT","volume":73421,"amount":983049.47,"timestamp":1751061317820},"volumeRatio":8.442055},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","floatShares":5900000,"roa":"-15.91%","roe":"-34.70%","lyrEps":-0.74,"volumeRatio":8.442055,"shares":21384400,"dividePrice":0,"high":14,"amplitude":0.082612,"preClose":13.86,"low":12.855,"week52Low":4.88,"pbRate":"1.90","week52High":19.58,"institutionHeld":0,"latestPrice":13.39,"eps":-0.648,"divideRate":0,"volume":676862,"delay":0,"ttmEps":-0.648,"open":14,"prevYearClose":16,"prevWeekClose":11.13,"prevMonthClose":10.44,"prevQuarterClose":7.51,"fiveDayClose":11.13,"twentyDayClose":10.3,"sixtyDayClose":8.29},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AARD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2545928425","title":"Aardvark Therapeutics Announces Phase 3 HERO Study Enrollment for ARD-101 in Prader-Willi Syndrome at 2025 United in Hope Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2545928425","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545928425?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:00","pubTimestamp":1750766419,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Announces Phase 3 HERO Study Enrollment for ARD-101 in Prader-Willi Syndrome at 2025 United in Hope Conference. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on June 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nNDL3lQtdK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4588","LU2210149790.SGD","LU2095319765.USD","AARD","IE00BGHQF748.EUR","BK4585","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","NDAQ","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2536637747","title":"Aardvark Therapeutics appoints Timothy Kieffer as CSO, Danny Villeneuve as CCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2536637747","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536637747?lang=en_us&edition=fundamental","pubTime":"2025-05-20 04:20","pubTimestamp":1747686024,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics (AARD) announced the appointments of key members of its leadership team, including Timothy Kieffer as chief scientific office...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-appoints-timothy-kieffer-as-cso-danny-villeneuve-as-cco?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-appoints-timothy-kieffer-as-cso-danny-villeneuve-as-cco?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0823414478.USD","BK4009","LU2506951792.HKD","LU2294711713.HKD","AARD","CCO","LU0823414551.USD","LU2249611893.SGD","LU2357125470.USD"],"gpt_icon":0},{"id":"2536637156","title":"Aardvark Therapeutics Inc. Strengthens Leadership Team with Key Appointments in Scientific, Commercial, Regulatory, and Legal Roles","url":"https://stock-news.laohu8.com/highlight/detail?id=2536637156","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536637156?lang=en_us&edition=fundamental","pubTime":"2025-05-20 04:10","pubTimestamp":1747685411,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. Strengthens Leadership Team with Key Appointments in Scientific, Commercial, Regulatory, and Legal Roles. Aardvark Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced key appointments to its leadership team. Timothy Kieffer, Ph.D., has been named Chief Scientific Officer, and Danny Villeneuve has been appointed Chief Commercial Officer. Additionally, Terrie Kellmeyer, Ph.D., joins as Senior Vice President of Regulatory Affairs, and Christian Zapf, J.D., takes on the role of General Counsel. These appointments aim to strengthen Aardvark's expertise as it advances its therapeutic programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDL9t9FVF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","AARD","IE00B3QW5Z07.USD","BK4588","LU2210149790.SGD","BK4112","BK4585","IE00BGHQF748.EUR","NDAQ","LU2210150020.SGD"],"gpt_icon":0},{"id":"2536637452","title":"Press Release: Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions","url":"https://stock-news.laohu8.com/highlight/detail?id=2536637452","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536637452?lang=en_us&edition=fundamental","pubTime":"2025-05-20 04:10","pubTimestamp":1747685400,"startTime":"0","endTime":"0","summary":"-- Timothy Kieffer, Ph.D., appointed Chief Scientific Officer. -- Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory. Danny Villeneuve brings more than 20 years of commercial leadership experience in the biopharmaceutical industry across U.S. and International markets. Most recently, he served as EVP, Chief Commercial Officer for Ironshore Pharmaceuticals, where he successfully led the commercial strategy and execution for the relaunch of their flagship product in the ADHD market. His leadership contributed significantly to the company's turnaround and subsequent acquisition by Collegium Pharmaceuticals. Prior to this role, Mr. Villeneuve commercialized products in the ADHD, C","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4120","TISI","BK4022","BK4232","R","AARD"],"gpt_icon":0},{"id":"2535878043","title":"Aardvark Therapeutics Is Maintained at Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2535878043","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535878043?lang=en_us&edition=fundamental","pubTime":"2025-05-15 23:59","pubTimestamp":1747324740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2025 11:59 ET (15:59 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2535829750","title":"Aardvark Therapeutics Inc trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2535829750","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535829750?lang=en_us&edition=fundamental","pubTime":"2025-05-15 21:48","pubTimestamp":1747316885,"startTime":"0","endTime":"0","summary":"09:40 EDT Aardvark Therapeutics (AARD) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-inc-trading-resumes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-inc-trading-resumes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2535582661","title":"Aardvark Therapeutics Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2535582661","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535582661?lang=en_us&edition=fundamental","pubTime":"2025-05-15 21:36","pubTimestamp":1747316219,"startTime":"0","endTime":"0","summary":"09:30 EDT Aardvark Therapeutics (AARD) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-inc-trading-halted-volatility-trading-pause?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-inc-trading-halted-volatility-trading-pause?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2535177328","title":"RBC Trims Price Target on Aardvark Therapeutics to $20 From $21, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2535177328","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535177328?lang=en_us&edition=fundamental","pubTime":"2025-05-15 18:22","pubTimestamp":1747304527,"startTime":"0","endTime":"0","summary":"RBC Trims Price Target on Aardvark Therapeutics to $20 From $21, Keeps Outperform, Speculative Risk","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AARD"],"gpt_icon":0},{"id":"2535883016","title":"BRIEF-Aardvark Therapeutics Reports First Quarter 2025 Financial Results And  Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2535883016","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535883016?lang=en_us&edition=fundamental","pubTime":"2025-05-15 05:21","pubTimestamp":1747257665,"startTime":"0","endTime":"0","summary":"BRIEF-Aardvark Therapeutics Reports First Quarter 2025 Financial Results And  Provides Business HighlightsMay 14 (Reuters) - Aardvark Therapeutics Inc AARD.O:AARDVARK THERAPEUTICS REPORTS FIRST QUARTE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUABVCSRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2535883038","title":"Aardvark Therapeutics Q1 EPS $(0.71) Down From $(0.55) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2535883038","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535883038?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:42","pubTimestamp":1747255323,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.71) per share. This is a 29.09 percent decrease over losses of $(0.55) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45421912/aardvark-therapeutics-q1-eps-0-71-down-from-0-55-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2535005600","title":"Aardvark Therapeutics Reports Q1 2025 Results: Net Loss Widens to $9.3M; R&D Expenses Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2535005600","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535005600?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:29","pubTimestamp":1747254543,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDLbD8wyh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2535073010","title":"Aardvark Therapeutics Inc - as of March 31, 2025, Aardvark Had Cash, Cash Equivalents, and Short-Term Investments of $151.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2535073010","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535073010?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:10","pubTimestamp":1747253400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUABVCSRQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2524145519","title":"Aardvark Therapeutics Price Target Maintained With a $50.00/Share by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2524145519","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524145519?lang=en_us&edition=fundamental","pubTime":"2025-04-01 23:16","pubTimestamp":1743520560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2025 11:16 ET (15:16 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2524897401","title":"Aardvark Therapeutics FY24 EPS (5.15) Down From ($1.82) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2524897401","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524897401?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:15","pubTimestamp":1743452149,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics FY24 EPS (5.15) Down From ($1.82) YoY","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44571255/aardvark-therapeutics-fy24-eps-5-15-down-from-1-82-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2524097441","title":"Press Release: Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2524097441","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524097441?lang=en_us&edition=fundamental","pubTime":"2025-04-01 04:10","pubTimestamp":1743451800,"startTime":"0","endTime":"0","summary":"-- Lead candidate ARD-101 demonstrated clinical activity and was generally. well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome ,with meaningful reductions in hyperphagia (up to a 16-point HQ-CT. reduction, with an average reduction of approximately 8 points among. subjects that followed trial protocol) observed during the 28-day dosing. -- DEXA scans analysis from the PWS Phase 2 trial data measuring body. composition indicated a trend toward decreased body fat (approximately. -- Aardvark bolstered its cash runway through the successful completion of. SAN DIEGO, March 31, 2025  -- Aardvark Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the full year ended December 31, 2024, and provided business highlights.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","PWS","IPO"],"gpt_icon":0},{"id":"2522658517","title":"BUZZ-Ultragenyx Pharma up after JPMorgan PT raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2522658517","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522658517?lang=en_us&edition=fundamental","pubTime":"2025-03-27 23:34","pubTimestamp":1743089680,"startTime":"0","endTime":"0","summary":"BUZZ-Ultragenyx Pharma up after JPMorgan PT raise** Shares of drugmaker Ultragenyx Pharmaceutical RARE.O rise 2% to $38.75** JPMorgan raises RARE's target price to $117 from $104** Believes RARE is uniquely positioned in the long term with a broad and diverse pipeline of orphan disease assets and a highly regarded management team - JPMorgan ** 19 of 20 brokerages rate the stock \"buy\" or higher, one \"hold\"; their median PT is $87, according to data compiled by LSEG** Up to last close, stock had fallen ~10% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nL3N3QA1CO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139","AARD"],"gpt_icon":0},{"id":"2522379307","title":"Aardvark Therapeutics Is Maintained at Buy by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2522379307","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522379307?lang=en_us&edition=fundamental","pubTime":"2025-03-27 22:25","pubTimestamp":1743085500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2025 10:25 ET (14:25 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2522371118","title":"Aardvark Therapeutics price target raised to $26 from $22 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2522371118","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522371118?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:41","pubTimestamp":1743075663,"startTime":"0","endTime":"0","summary":"BofA analyst Tim Anderson raised the firm’s price target on Aardvark Therapeutics (AARD) to $26 from $22 and keeps a Buy rating on the shares after...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-price-target-raised-to-26-from-22-at-bofa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-price-target-raised-to-26-from-22-at-bofa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2518220552","title":"Aardvark Therapeutics Inc : Bofa Global Research Initiates Coverage With Buy Rating; Price Objective $22","url":"https://stock-news.laohu8.com/highlight/detail?id=2518220552","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518220552?lang=en_us&edition=fundamental","pubTime":"2025-03-10 22:04","pubTimestamp":1741615472,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nFWN3PT13T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2518274832","title":"BofA Initiates Aardvark Therapeutics at Buy With $22 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2518274832","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518274832?lang=en_us&edition=fundamental","pubTime":"2025-03-10 22:00","pubTimestamp":1741615239,"startTime":"0","endTime":"0","summary":"Price: 10.60, Change: +0.47, Percent Change: +4.64","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AARD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AARD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-14","symbol":"AARD","fiscalQuarterEnding":"2025/03","expectedEps":-0.7,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2025-03-31","symbol":"AARD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AARD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AARD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AARD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AARD","date":"2025-06-26","current":-12.037635,"percent":0.382022,"low":-51.17654,"twenty":-29.768429,"median":-10.548868,"eighty":-8.329026,"high":-7.114571,"avg":-17.485489,"sd":12.075518,"marketCap":333683249},"quantilePoints":[{"date":"2025-02-21","current":-51.17654,"twenty":-46.993414,"median":-42.216938,"eighty":-39.920668,"marketCap":368880503},{"date":"2025-02-28","current":-39.75453,"twenty":-42.139802,"median":-40.229211,"eighty":-39.232381,"marketCap":286550651},{"date":"2025-03-07","current":-28.243517,"twenty":-40.603022,"median":-39.176012,"eighty":-36.900511,"marketCap":203579269},{"date":"2025-03-14","current":-31.091602,"twenty":-40.336014,"median":-37.766803,"eighty":-30.723725,"marketCap":224108270},{"date":"2025-03-21","current":-27.23482,"twenty":-39.944402,"median":-34.681377,"eighty":-29.198812,"marketCap":196308580},{"date":"2025-03-28","current":-26.404128,"twenty":-39.576524,"median":-30.913597,"eighty":-27.946841,"marketCap":190320955},{"date":"2025-04-04","current":-9.026143,"twenty":-39.119644,"median":-30.068072,"eighty":-27.341623,"marketCap":185830236},{"date":"2025-04-11","current":-7.397773,"twenty":-38.751766,"median":-29.400552,"eighty":-17.252871,"marketCap":152305358},{"date":"2025-04-17","current":-7.977371,"twenty":-38.300819,"median":-28.45119,"eighty":-8.603741,"marketCap":164238114},{"date":"2025-04-25","current":-8.66235,"twenty":-37.766803,"median":-27.946841,"eighty":-8.371497,"marketCap":178340462},{"date":"2025-05-02","current":-11.939711,"twenty":-36.900511,"median":-27.412825,"eighty":-8.371497,"marketCap":245814773},{"date":"2025-05-09","current":-11.307423,"twenty":-34.865316,"median":-26.68597,"eighty":-8.46634,"marketCap":232797221},{"date":"2025-05-16","current":-7.114571,"twenty":-32.693651,"median":-13.552046,"eighty":-8.46634,"marketCap":197215912},{"date":"2025-05-23","current":-7.834638,"twenty":-31.0204,"median":-11.823792,"eighty":-8.360959,"marketCap":217176159},{"date":"2025-05-30","current":-8.061615,"twenty":-30.818661,"median":-11.433881,"eighty":-8.172533,"marketCap":223467976},{"date":"2025-06-06","current":-9.353039,"twenty":-30.367714,"median":-11.107198,"eighty":-8.178795,"marketCap":259266244},{"date":"2025-06-13","current":-8.656453,"twenty":-30.076972,"median":-10.833207,"eighty":-8.210998,"marketCap":239956875},{"date":"2025-06-20","current":-9.454788,"twenty":-30.053238,"median":-10.188135,"eighty":-8.218152,"marketCap":262086713},{"date":"2025-06-26","current":-12.037635,"twenty":-29.768429,"median":-10.548868,"eighty":-8.329026,"marketCap":333683249}],"updateTime":1751056645956}}}